corrective actions must be appropriate For the fixer retention test Mr. Christopher J. Worrell loans CEO CorePharma LLC 215 Wood Avenue Middlesex New Jersey 08846

For example In your response However

In addition In addition In your response In addition During your routine AQL in-process inspection Prior to packaging Conducted as part of the investigation In your response

However However

For example 10-008.00 211.110(a)] Also 2010 response to the FDA483 to implement statistical process control However For example 43% of Ropinirole HCI 2mg tablets

lot CPI874 In your response

However For example you failed to comply with SOP 25-031-04 Your response appears adequate; however For example

Potassium Citrate 10mEq tablets In your response

For example strength quality

10 Waterview Boulevard 3rd Floor Parsippany New Jersey 07054 Attn: Andrew Ciaccia Whitney Labs c/o Colonial Management Group LP T. Mark Gallagher President/CEO 14050 Town Loop Boulevard Suite 204 Orlando Florida 32837 On March 12

and 17 Suites #1-4

Ormond Beach We acknowledge receipt of your April 14 2008 written response to the FDA 483 However However In addition

Lot #5364L measure Your firm's April 14 response is not adequate for the reasons listed above alleviate our concerns regarding the identity